Combining Scientific Understanding
with Business Experience
Combining Scientific Understanding
with Business Experience
Fred Cohen, M.D., D. Phil., Partner and Managing Director

Fred Cohen, M.D., D.Phil., Partner and Managing Director

Prior to joining TPG Biotechnology in 2001, Dr. Cohen was a Professor of medicine, cellular and molecular pharmacology, biochemistry and biophysics and pharmaceutical chemistry at UCSF. In this context, he was Chief of the Division of Endocrinology and Metabolism and directed an active research program in the areas of prion biology, structure based drug design, bioinformatics and heteropolymer chemistry. Dr. Cohen is a Fellow of the National Academy of Medicine (formerly the IOM), the American Academy of Arts and Sciences, American College of Physicians, a member of the American Society for Clinical Investigation and the Association of American Physicians, and the recipient of several awards and honors including the Burroughs-Wellcome New Initiatives in Malaria Award, the LVMH Science Pour L’Art Prize (shared with Stanley Prusiner), a Searle Scholars Award and Young Investigator Awards from the Endocrine Society and the Western Society for Clinical Investigation. He graduated magna cum laude from Yale University in 1978 and received his D.Phil from Oxford University as a Rhodes Scholar in 1980, his M.D. from Stanford Medical School as an American Cancer Society Postdoctoral Fellow in 1984 and his internal medicine and endocrinology training at UCSF. He joined TPG in 2001 to initiate TPG’s venture efforts in biotechnology and life sciences. He currently serves on the board of directors of: Acumen, Inc.; BioCryst, Inc. (Nasdaq: BCRX); CareDx, Inc. (Nasdaq: CDNA); Five Prime Therapeutics, Inc. (Nasdaq: FPRX); Genomic Health, Inc. (Nasdaq: GHDX); Progyny; Quintiles Transnational Corporation (NYSE: Q); Rapid Micro Biosystems Inc.; Roka Bioscience, Inc. (Nasdaq: ROKA); Tandem Inc. (Nasdaq: TNDM); and Veracyte, Inc. (Nasdaq: VCYT).

Heath Lukatch, Ph.D., Partner and Managing Director

Heath Lukatch, Ph.D., Partner and Managing Director

Prior to joining TPG Biotech in May 2015, Dr Lukatch was a Partner at Novo Ventures (US), where he helped establish Novo Ventures’ San Francisco office. During his 9 years at Novo, Dr. Lukatch served as Chairman of Cianna Medical, Inogen (Nasdaq: INGN), NTP and Spinifex Pharmaceuticals, and he served as a board member at Amira Pharmaceuticals (acquired by BMS in 2011), AnaptysBio, Elevation Pharmaceuticals (acquired by Sunovion in 2012), Flexion Therapeutics (Nasdaq: FLXN), FoldRx Pharmaceuticals (acquired by Pfizer in 2010), InSound Medical (acquired by Sonova in 2010), Nora Therapeutics and Synosia Therapeutics (acquired by BioTie in 2011), he was also a board observer at Alios BioPharma (acquired by J&J in 2014). Prior to joining Novo Ventures (US), Dr. Lukatch was a Managing Director responsible for biotechnology venture investments at Piper Jaffray Ventures and SightLine Partners, where his investments included Dynavax (Nasdaq: DVAX) and Fluidigm (Nasdaq: FLDM). Before Piper Jaffray Ventures, Dr. Lukatch worked as a strategy consultant with McKinsey & Company, where he was a leader in McKinsey’s biotechnology practice. Dr. Lukatch also served as co-founder and CEO of AutoMate Scientific, a biotechnology instrumentation company, and he has held scientific positions with Chiron, Roche Bioscience and Cetus, doing molecular biology, electrophysiology and protein chemistry, respectively. Dr. Lukatch received his Ph.D. in Neuroscience from Stanford University where he was a DOD USAF Fellow, and his B.A. with high honors in Biochemistry from the University of California at Berkeley.

Eran Nadav, Ph. D., Principal

Eran Nadav, Ph.D., Partner and Managing Director

Dr. Nadav joined TPG Biotech in 2007 to invest in global pharmaceuticals and biotechnology. He invests in a broad range of early to late stage companies and products, including innovative therapies and high value generics.

Prior to TPG, Dr. Nadav served as Business Development Director at Eisai, where he evaluated and negotiated notable licensing and acquisition deals. Prior to this he worked for the Israeli office of JJDC, the venture capital subsidiary of Johnson & Johnson, where he analyzed and executed investments in innovative technologies and biopharmaceuticals. Previously, Dr. Nadav worked for Neurim Pharmaceuticals Ltd. supporting the clinical development of Circadin®. He holds a Ph.D. in biochemistry, M.Sc. magna cum laude, B.Sc. magna cum laude, and MBA - all from Tel Aviv University.

Dr. Nadav currently serves as Chairman of the Board of Trevi Therapeutics, and board member at Collegium Pharmaceutical (Nasdaq: COLL), ShangPharma (a China-based CRO), and NovaSom. He was the Chairman of the Board of Ultragenyx Pharmaceutical (Nasdaq: RARE) from January 2012 to June 2015. Other past investments and board roles include JCR Pharmaceuticals (a Japanese biopharma company; TSE: 4552), MacroGenics (Nasdaq: MGNX), and Mayanot Eden.

Heather Preston, M.D., Partner and Managing Director

Heather Preston, M.D., Partner and Managing Director

Prior to joining TPG Biotech in May 2005, Dr. Preston spent two years at JP Morgan Partners where she focused on medical device and biotechnology venture capital investing. Prior to JP Morgan Partners, Dr. Preston was an Entrepreneur-in-Residence with New Enterprise Associates. She also spent five years at McKinsey & Co. in New York, where she was a leader of their pharmaceutical and medical products consulting practice. She advised large pharmaceutical companies and biotechnology companies on critical strategic issues such as R&D portfolio prioritization, M&A opportunities, new technology acquisitions, new product launches and product growth strategies. Dr. Preston has an undergraduate degree in biochemistry from the University of London and a medical degree from the University of Oxford. Dr Preston completed a post-doctoral fellowship in molecular biology at the Dana Farber Cancer Institute, Harvard University and trained in Internal Medicine at the Massachusetts General Hospital and sub-specialized in Gastroenterology and Hepatology at UCSF. During her academic medical career, she was the recipient of a Fulbright Scholarship, a Fulbright Cancer Research Scholarship, a Harlech Scholarship and a Science and Engineering Research Council Post-doctoral Fellowship Award.

Dr. Preston co-founded Virobay Inc., a biotechnology company which is seeking to develop new therapies for the treatment of pain and auto-immune diseases. Dr. Preston currently serves on the board of directors of Albireo, Inc.; Alder BioPharmaceuticals (Nasdaq: ALDR); Otonomy, Inc. (Nasdaq: OTIC); Unchained Labs and Virobay, Inc. She previously served on the boards of Aptalis Pharma (acquired by Forest Labs in February 2014), Conventus, Vibrynt, VLST and Elevation Pharmaceuticals (acquired by Sunovion in September 2012) and is responsible for overseeing TPG Biotech’s investment in Par Pharmaceuticals.

Cayce Denton, Associate

Cayce Denton, Vice President

Prior to joining TPG Biotechnology in 2010, Ms. Denton managed finance for the Nutropin and Lytics franchises at Genentech, Inc., where she also participated in a CFO Rotation Program consisting of time in R&D Finance, Financial Planning and Analysis, Audit and Treasury. Prior to Genentech, Inc., she was in Business Development at Novartis in Cambridge, where she helped execute an approximately $700 million partnership with Alnylam Pharmaceuticals, Inc. Prior to Novartis, Ms. Denton worked in biotech venture capital at Atlas Venture and was an investment banker with Credit Suisse First Boston’s Technology Group, in Boston. Ms. Denton has an MBA from the Wharton School of the University of Pennsylvania, where she was awarded the F. H. Shields Fellowship and co-founded the Biotech Investment Group, and a B.S. from M.I.T. in Biology. Ms. Denton is a board member of Karos Pharmaceuticals, Inc., PatientSafe Solutions, Inc., and Trevi Therapeutics, Inc.; and a board observer of Acumen, Inc.

Peter Bojo, Analyst

Peter Bojo, Analyst

Prior to joining TPG Biotechnology in 2014, Mr. Bojo worked in management consulting at Oliver Wyman for 3 years with projects including strategy and M&A engagements within healthcare and financial services. Prior to Oliver Wyman, he worked in R&D at a medical device startup. Mr. Bojo has a Master’s and a B.S. from M.I.T. in Bioengineering, has co-authored several papers, and is a member of Tau Beta Pi and Phi Beta Kappa honor societies.